Donepezil for the management of patients with Alzheimer's disease: A good choice from among the cholinesterase inhibitors

Drugs and Therapy Perspectives

Volumn 17, Issue 11, 2001, Pages 1-6

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; ARTICLE; BRADYCARDIA; CANCER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FALLING; FLUSHING; HEART ATRIUM ARRHYTHMIA; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NIGHTMARE; PANIC; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEIZURE; SHORT COURSE THERAPY; SYNCOPE; VOMITING;

EID: 0035806201     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-200117110-00001     Document Type: Article

References (28)

1. Donepezil: A review of its use in Alzheimer's disease
2. Donepezil: An anticholinesterase inhibitor for Alzheimer's disease
3. Donepezil: Pharmacoeconomic implications of therapy
4. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial: The Donepezil Study Group
5. Cholinesterase inhibitors for Alzheimer's disease
6. Galantamine: A review of its use in Alzheimer's disease
7. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study
8. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
9. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
10. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease
11. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society
12. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease - Results of a preliminary evaluation
13. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of US multicentre open label extension study
14. An Evaluation of the long-term efficacy of donepezil in patients from a phase III clinical extension trial
15. Guidelines on drug treatments for Alzheimer's disease
16. Donepezil use in Alzheimer disease
17. Treatment of cognitive impairment in Alzheimer's disease
18. Cognitive function and the costs of Alzheimer disease
19. Alzheimer's disease care: Costs and potential savings
20. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
21. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 8-weeks double-blind parallel study in two groups, 2 mg/day, 0.1 mg/day
22. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 24-48 weeks double-blind, placebo-controlled study
23. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 12-weeks double-blind, placebo-controlled study, 3 mg/day, 5 mg/day